跳至主要内容
临床试验/NCT00365924
NCT00365924已完成不适用

A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo)

Pfizer1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
20
试验地点
1
主要终点
Changes in bone quality parameters (micro- and macroarchitecture) in osteoporotic postmenopausal women following 12 months of therapy with Forteo

研究概览

简要总结

This methodology trial will be conducted in patients with osteoporosis and will measure the changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone density following therapy with the approved drug, Forteo.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
55 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Postmenopausal women with osteoporosis

排除标准

  • Any therapies or products affecting bone turnover within 12 months of Screening.
  • Bisphosphonate treatment >1 month in total duration at any time in the past.
  • In addition, patients must be bisphosphonate-treatment-free for at least 12 months prior to Screening.

研究组 & 干预措施

Forteo

Other

干预措施: Forteo (Drug)

结局指标

主要结局

Changes in bone quality parameters (micro- and macroarchitecture) in osteoporotic postmenopausal women following 12 months of therapy with Forteo

时间窗: 12 months

次要结局

  • Changes in BMD and bone biomarkers following 12 months of therapy with Forteo(12 months)

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验